Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. We have developed and manufactures more than 65 products sold by customers worldwide.

We have the expertise and proven track record to guide projects from clinical research stages through optimization, validation, and approval. We operate seven facilities in the US and Europe, equipped to facilitate efficient drug product development and manufacturing, maintaining excellent environmental conditions compliant with US and EU cGMP regulations.

Adare has dedicated high potency GMP manufacturing and development areas. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care.

Althena Medical is the answer to your drug delivery device development.
We are specialized in syringes, droppers and oral dosers in COP (Cyclic Olefin Polymer), COC (Cyclic Olefin Copolymer) and PP (Polypropylene) development and we guarantee maximum flexibility during project and production phases. Our thorough skills in meeting client needs is thanks to our internalization of the project and design phases as well as production, assembly and final sterilization.
We can thus guide you with the drug delivery device, whether your company needs large production batches or whether the analysis of your product is still in the preclinical and experimental phases.

Aprecia is the biopharmaceutical leader in advanced additive manufacturing technologies. As a specialty CDMO,
we help you overcome formulation challenges. Through novel oral dosage forms, we are reimagining medicine so patients and caregivers can live their best lives.

We are Ardena, a reputable contract partner delivering drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with you to compile your regulatory dossier and to fast track your product towards compliance. Every day, we guide companies through the hurdles and challenges of drug development. Our integrated service offering helps to streamline the drug's progress to clinic and beyond. Ardena is your one source contractor for the chemical and pharmaceutical development of your valued compounds. In parallel, we provide you with full product analytical and bioanalytical support during development. Our dossier-centric approach makes a difference. We work with you to compile your regulatory dossier in parallel with drug development, saving you time, identifying hurdles and fast-tracking your product to compliance. We are experts in writing and formatting supporting CMC documentation.

Asahi Kasei is a highly diversified Japanese supplier of high-performance materials for various industries, including automotive, energy, electronics, housing and health care. In the fields of pharma- and nutraceuticals, we offer functional excipients. For many decades Asahi Kasei stands for quality, reliability and performance and is dedicated to “Creating for Tomorrow”.

Our key product is Ceolus, functional grades of microcrystalline cellulose (MCC) with outstanding compactability and flowability due to a special particle structure. This allows for avoiding typical formulation challenges like tablet mass segregation, capping, slow/fast disintegration, low tablet hardness or the changing of the API structure. Celphere, Asahi Kasei’s MCC spherical cores allow the combination of incompatible APIs in one tablet, achieve different release profiles and improve the acceptability of products. Special grades of our pregelatinized starch PC-10 can be applied for the protection of moisture sensitive APIs in the formulation.

Our functional excipients prove to be solutions to our customer’s daily challenges.

Ashland works alongside formulators to advance drug-specific delivery platforms with an industry-leading portfolio of pharmaceutical excipients and technical expertise including superior polymer technology and systems for optimum bioavailability.

For over 50 years, Ashland has created value for customers through applications knowledge, technical support, and a powerful product portfolio. The company offers real-time solutions based on superior binder, film coating, solubilizer, disintegrant, rheology control, cyclodextrins and modified-release technologies.

A team of technical experts at global R&D centers provide formulation development support for conventional and potent compounds as well as controlled substances to offer tailored solutions that address solubility challenges.

During this event, Ashland will showcase polymer solutions for extended release injectable depot strategies including ViatelTM bioresorbable polymers. This portfolio includes 72 GMP grades of lactide, glycolide and caprolactone copolymers as well as a customized polymer platform which supports formulators to solve complex processing, stability and delivery challenges.

Focusing On Your Formulation Needs
BASF produces excipients and active ingredients of outstanding quality and performance. With our unique expertise in polymer chemistry, our research & development capabilities and our clear commitment to developing excipients, BASF has continuously created solutions that contribute to your success and to more efficient pharmaceuticals. We deliver value added functional solutions to your formulation challenges by leveraging our expertise in delivery systems and related technologies. Our team of experienced industry specialists support you in developing effective, reliable formulations – giving you a vital advantage in a highly competitive market.

Our Platforms – Your Access To BASFs Solution Offer
BASF has been committed to the pharmaceutical industry since we introduced our original Kollidon® in the early 20th century. Since then we have continuously expanded our solution offer. Today we solve unmet formulation needs and offer intelligent solutions for today and tomorrow's challenges in drug formulation. Our four dedicated solution platforms based on current pharmaceutical market needs help you to find what you are looking for – faster than ever before. We can help with formulation challenges related to Instant and Modified Release, Solubilization, Skin Delivery, Softgels and Biologic Solutions

Cambridge Consultants (CC) is the deep tech powerhouse of the Capgemini Group. Deep tech is a mindset, a bold strategy that harnesses radical science and engineering to achieve things no-one else can. It delivers transformative business value and growth for our clients, who gain defendable commercial and operational advantage from new-to-the-world products, services and processes that they own. We overcome the ultimate business challenge: turning something that doesn’t yet exist into a reality. Our advice is built on practice, with over 750 scientists, engineers, designers and consultants working globally across more than 20,000 sq. m of state-of-the-art R&D facilities. As part of Capgemini Invent, CC is backed by 340,000+ Capgemini team members in more than 50 countries.

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen’s Kyprolis®, Baxter International’s Nexterone®, Spectrum’s EVOMELA® and Melinta Therapeutics’ Baxdela™. There are many Captisol-enabled products currently in various stages of development.

Catalent specializes in comprehensive development, analytical and bioavailability enhancement from candidate selection to fully integrated solutions, to help get customers’ drugs to clinic faster. Using a rigorous, data-driven scientific approach, API-sparing techniques and advanced formulation technologies within a global network, Catalent helps solve complex challenges to accelerate drug development.

Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, core excipients and functional packaging for the pharmaceutical and nutraceutical industries. Our best-in-class products and technologies are complemented by extensive application data and expertise to support all phases of solid oral dose formulation. Colorcon’s focus on market issues and technology innovation has earned the company an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical excellence, extensive regulatory knowledge and reliable supply from multiple locations.

Conscio Group is a fully certified CRDO (Contract Research, Development Organization)
partner, delivering integrated pharmaceutical development services across the entire
product lifecycle.

We specialize in complex product development and innovative drug delivery solutions,
including solid, semi-solid, and special dosage forms. Our end-to-end services cover
formulation development, process scale-up, GMP manufacturing of clinical and
registration batches, in-house clinical trials, and bioanalytical services.

With strong expertise in high-potency APIs (all OEB classes), controlled substances, and
enabling technologies for bioavailability improvement, we help our partners de-risk
development and accelerate time-to-market. Headquartered in Munich, with sites in
Germany, Czech Republic, Austria, Slovakia and a US representative office.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Curia’s network of sterile drug product facilities support partners from formulation development to commercial manufacturing in various formats including vials, pre-filled syringes, and cartridges. With over 30 years of experience formulating both large and small molecules for injection, you can rely on Curia.

DFE Pharma is a global leader in the development, production and supply of high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, OSD, ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients. With more than a century of experience and around 450 people worldwide, we serve over 5,000 customers in 100+ countries. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies to improve patient’s lives, driven by our purpose: Your medicines, and our solutions. Moving to a healthier world.

digiM is a technology leader providing CRO services in microstructure analysis and in silico modeling for the development of drug products. Combining advanced microscopic analysis with computational physics, digiM's platform provides a full spectrum understanding of drug product properties and performance. digiM works closely with developers to navigate program challenges and institutionalize knowledge libraries. In addition to services, digiM provides I2S, a cloud-based image analytics and data management platform.

As innovators in nutrition, health, and beauty, we reinvent, manufacture, and combine vital nutrients, flavors, and fragrances for the world’s growing population to thrive.
In the Biomedical division, we serve as a committed partner in driving sustainable innovation in healthcare, from spark to solution. Our biomaterial products, customized solutions and expert services are recognized for their unmatched quality, reliability, and performance worldwide.
Together, we bring progress to life every day, everywhere, for billions of people.To learn more, visit

Eurofins CDMO is a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with Active Pharmaceutical Ingredients (APIs)/Drug Substance and Drug Product development for biologicals and small molecules. Science is our foundation and allows us to support small and major biopharmaceutical companies achieving their pre-clinical and clinical milestones on time.

We are experts in breakthrough technologies for API development, highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs…).

Our services: API/DS Development, Solid State R&D, Preformulation, Formulation Development, GMP Manufacturing, Clinical Packaging and Logistics, CMC Regulatory Support.

Our highly-qualified project management team will propose a complete drug development strategy. Frequent communication through one single point of contact, our team's flexibility, troubleshooting mindset, customized solutions will help speed up the drug development process. Operating under strict quality procedures, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

galien+ is a CDMO with 3 manufacturing sites in France.
@ Auxerre
The site offers a wide range of manufacturing capabilities, with a strong focus on solid doses, powder sachet filling and a dedicated high potent drugs facility.
@Nevers
The site is specialized in LyoDis®/ LYOC - Lyophilized freeze dried tablets (ODT) and has dedicated R&D team and a pilot plant for tailor made development.
@ Sens
The Site offers capacities in bottles & blister packaging, quality control, stability studies and a wide range of pharmaceutical services from analytical development & validation.

Galvita is a pioneer in formulation development located in Basel, Switzerland. Galvita’s patented and repeatedly clinically tested technology enables the production of micro capsules (Templated Inverted Particles / TIP) that can be loaded with many different APIs and easily compressed to tablets with excellent mechanical strength. TIP based tablets offer many benefits, such as ultra-rapid disintegration, fast onset of action, water-free ingestion, smaller tablet sizes, taste masking and a neutral product composition (100% pure calcium phosphate, compendial and inorganic material). Galvita offers several formulation service packages, R&D and clinical testing support, as well as exclusive and non-exclusive licensing options.

Visit us at www.galvita.com for more information.

Since 1880, Gattefossé has been developing, manufacturing and selling pharmaceutical excipients and cosmetic ingredients of natural origin for the health and beauty industries worldwide. Gattefossé offers to the pharmaceutical industry innovative lipid excipients for oral solubilization, bioavailability enhancement, sustained release, lubrication, and taste-masking. We provide skin penetration enhancers and emulsifiers for improved topical formulations. Every product is designed with utmost attention to safety, quality, and performance consistency. As part of Gattefossé offer, technical and regulatory support is provided by fully trained experts to accelerate customers’ drug development programs thanks to our 4 Technical Centers of Excellence in France, China, India and the United States.

Environmental and social issues have always been part of our culture. Today, Gattefossé relies on a purposeful CSR approach, Gatt’Up&Act, to build its innovation and development strategy.

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer psroduces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

Glatt Pharmaceutical Services GmbH & Co. KG is the CDMO division of the Glatt Group. We develop solid pharmaceutical dosage forms with a focus on multiparticulate systems, such as pellets, granules, tablets, and capsules. We offer innovative solutions to achieve drug solubility enhancement by amorphous solid dispersions. Functional coating for taste masking and controlled drug release is another key expertise at our sites Binzen, Germany and Ramsey, New Jersey.

Our service portfolio covers the full range from feasibility studies and the formulation development over the production of clinical samples up to the bulk manufacturing of pharmaceuticals. The storage, commissioning, as well as the distribution organization of clinical samples and pharmaceuticals for market supply complete our service portfolio. In this sector, we also offer additional logistic services for import, export, and cold chain management.

Grand River Aseptic Manufacturing, Inc. (“GRAM”) is a leading contract development and manufacturing organization with advanced equipment and innovative technology that delivers customized solutions to meet clients’ fill and finish needs for liquid vials, lyophilized vials, syringes, and cartridges. With biologic, small molecule, and vaccine capabilities, Grand River Aseptic Manufacturing supports pharmaceutical development, cGMP manufacturing, analytical testing, and regulatory filing.

Hovione offers customized services and innovative solutions from drug substance to drug product, with all activities performed at the same site. Hovione provides a fully integrated service for clinical and small commercial scale complex drug product development and manufacturing as well as formulation development for highly sophisticated inhalation and other formulations both for small molecules and biologics. As the Leader in Commercial Spray Drying, Hovione can handle projects from early-phase development to commercial and accelerates your time to market. Our particle engineering technologies can address challenges in solubility enhancement, lung delivery, modified release and taste-masking applications and can handle highly potent compounds. For biopharmaceuticals Hovione is investing by partnering in specialized particle engineering technologies, namely spray drying, aseptic spray freeze drying, nanoparticles and microemulsions. We do well what is difficult, to give our customers what they cannot find elsewhere

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long-acting injectables (LAI) for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Using biodegradable polymers for microspheres, gels and implants (including ISFI) we have a unique platform to control sustained drug delivery of small molecules, peptides and proteins (including mAbs) from days, weeks to months (6).

InnoGI Technologies (formerly The TIM Company) provides innovative CRO services to the Pharmaceutical Industry related to Gastrointestinal (GI) research and Oral Drug Delivery. It utilizes the most advanced and accurate gastrointestinal technology, mimicking the dynamics of a real human gut (SurroGUT™). Our SurroGUT™ platform offers the TIM systems, a technology that is able to mimic the human GI tract with a correlation range of 76% to 99.9% with human formulation rankings. This innovative solution provides enhanced predictive capabilities, aiming to improve the overall probability of success, also in preparation for clinical trials.

InnoGI Technologies, headquartered in Delft, The Netherlands, offers a range of research services addressing complex formulation issues in oral drug candidates which can lead to decreased formulation iterations, effectively de-risked clinical trials, and shortened time-to-market. InnoGI Technologies is driven by the goal of developing innovative technologies and solutions related to realistic GI tract simulations and oral drug delivery for Pharma and Food.

KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.

Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. With world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. www.kbibiopharma.com.

Based on 60 years of experience in the development and manufacturing of scientific instruments, KNAUER also offers custom engineering of equipment for the laboratory and for GMP production.

The company’s most recent development in this field – lipid nanoparticles (LNP) production systems – have enabled the large-scale manufacturing of mRNA-based vaccines to fight the Corona pandemic.

Traditionally, KNAUER is best known for its high-precision liquid chromatography systems (HPLC and FPLC) and related components. The systems are used to analyze samples for ingredients and impurities and determine their quantities, both in the laboratory and in process analysis. The systems can also purify value substances such as active pharmaceutical ingredients on a laboratory scale.

KNAUER’s valves, pumps, detectors, and other components are also used for tasks such as high-pressure dosing and various flow detection tasks in different applications. OEM manufacturing LC components for other suppliers is an important part of KNAUER’s business.

Leukocare is a formulation development partner specializing in biologics, applying bioinformatics-driven preselection and empirical design to develop molecule-specific solutions. Our proprietary, data-guided approach accelerates identification of excipients and formulation parameters, reducing timelines and conserving drug substance.

With over 50 sterile injectable molecules developed annually, we bring broad modality expertise—including highly concentrated mAbs, recombinant proteins, peptides, small molecules, viral vectors, and enveloped viruses.
Using a robust analytical toolbox and statistically powered Design of Experiments (DoE), we generate stable, scalable formulations supported by early long-term stability projections.

We offer flexible formulation formats including liquid, lyophilized, and spray-dried, with fallback strategies for challenging targets. Our adaptive, collaborative process integrates seamlessly with internal development pipelines, ensuring technical rigor, regulatory foresight, and tailored outcomes.

Lipoid – We Invest in Quality

The Lipoid Group is the world’s leading supplier offering a fully comprehensive range of phospholipids - high purity natural, hydrogenated as well as synthetic products and pre-formulations. Naturally derived raw materials and environmentally friendly processes are the basis of our wide range of products.

Lipoid’s phospholipids are an essential premise for state-of-the art pharmaceutical dosage forms and advanced drug delivery systems, such as emulsions, liposomes, mixed micelles, and lipid nanoparticles.

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of approximately 18,500 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. We support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

In Advanced Synthesis, we apply more than 125 years’ expertise in classic and complex chemistry to the manufacturing of small molecules, highly potent APIs, antibody-drug conjugates and bioconjugates.

Find out more at www.lonza.com
Follow @Lonza on LinkedIn

As a trusted technology partner for the pharmaceutical industry, LTS develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Lubrizol provides excipients that enhance the solubility and bioavailability of active ingredients. Apinovex™ Polymers are used for amorphous solid dispersions, improving the solubility of poorly soluble drugs. Apisolex™ Polymers enhance solubility in injectable formulations, offering high drug loading and stability.

Carbopol® Polymers are high molecular weight polyacrylic acid polymers used in various formulations for their thickening and stabilizing properties. We also supply a range of other ingredients listed on the FDA’s Inactive Ingredient Database (IID) that can help improve the feel and performance of topical pharmaceutical formulations.

Nanexa is a pioneering pharmaceutical company dedicated to the development of innovative drug delivery systems. At the forefront of its technological advancements is the PharmaShell® technology, designed for long acting injectables. This cutting-edge technology harnesses the power of nanotechnology to create a shell around the active pharmaceutical ingredient, enabling controlled and sustained release over extended periods. PharmaShell® holds the potential to transform treatment paradigms across various therapeutic areas by improving patient compliance, reducing dosing frequency, and enhancing efficacy. Nanexa’s commitment to innovation and excellence in drug delivery is underscored by its robust research and development efforts and strategic collaborations with industry leaders. As Nanexa presents PharmaShell® at this conference, it aims to showcase the technology’s capabilities and its impact on the future of long acting injectables, fostering new partnerships and advancing the field of pharmaceutical sciences.

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline to progress to clinical development. CESS® enables lower dosage and safer products to be developed with reduced side-effects and permits combination therapies, which would otherwise be prohibited by the large dosages of either drug. The award-winning technology is also ushering in a new era of ocular, pulmonary and transdermal drug delivery applications, along with enhanced delivery of drug particles across the blood-brain barrier.

Nisso Chemical Europe offers NISSO HPC, a high-quality excipient for the pharmaceutical industry providing hydroxypropyl cellulose in a wide range of viscosities and particle sizes for diverse applications, offering solutions for direct compression, roller compaction, wet granulation, drug solubility enhancement (amorphous solid dispersions, nanosuspensions), supersaturation stabilizer, controlled release hydrophilic matrix systems, 3D tablet printing, extrusion, orodispersible tablets, injectables, and film coating.

Pfanstiehl Inc. is a cGMP Manufacturer of High Purity Low Endotoxin components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as L-Arginine, Histidine, Glutamine and Methionine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan Illinois USA. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

PharmaCircle is a leading information provider to the life sciences industry, providing pipeline and products intelligence, business prospecting tools, curated formulation and component details, supply chain insights, and other information solutions to subscribers. PharmaCircle’s Drug Delivery Technology Reviews provide in depth comparative analysis on more than 9,000 drug delivery technologies and delivery devices, including strengths/limitations, patents, deals, and the products associated with the technologies.
To learn more, visit www.pharmacircle.com.

Pion Inc. offers unique instruments and services for informed drug and food formulation decisions, spanning R&D to manufacturing. Pioneering in vitro to in vivo tools, we optimize drug development and provide insights for pharmaceuticals and biopharmaceuticals. Our mission: expedite drug development, serving a global market with two decades of trusted expertise. Headquartered in Massachusetts, USA, and a UK office for global reach, Pion Inc. advances pharmaceuticals through innovation.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.

Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, through more than 30 manufacturing sites, has a turnover of around 5 billion euros, and employs around 10,000 people worldwide.

Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant-based cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition and health markets. We truly unlock the potential of nature to improve, cure and save lives.

Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.

Selvita is one of the leading preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.
Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development, both for small molecules and therapeutic antibodies. On top of that, Selvita also offers analytical support for drug development and contract testing studies.

Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are in Krakow (HQ), Poznan and Wroclaw Poland, and Zagreb, Croatia. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.

Seppic, an Air Liquide Healthcare company, has been a subsidiary of the Air Liquide Group since 1986. For over 75 years, Seppic has developed, manufactured, and marketed unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary, and industrial products. Across the world, Seppic has created a vast team of women and men who love what they do in service to their customers, and to the health, well-being, and beauty of all.

As an expert in surfactants, polymers, and formulation, Seppic offers pharmaceutical excipients adapted to oral, topical, and parenteral routes of administration. Its ingredients range from film coatings for tablets to injectable solubilizers and polymers for dermopharmacy. For over 25 years, Seppic has also offered high-performance adjuvants for therapeutic vaccines. Now, our work has expanded to involvement in prophylactic vaccines.

QPharma, Foster Delivery Science and Disphar International are now Sever Pharma Solutions. Together we have formed a new CDMO, a company that can provide our customers with unique capabilities and expertise. Sever Pharma Solutions brings your pharmaceutical ideas to life by offering expertise in high potent drug development, a drive to enhance performance, a passion for perfection, and a commitment to be your partner through the whole journey. We can enhance your reach by ensuring that your products can benefit patients all over the world. We can enhance your efficiency by providing you with a complete value chain to offer you an optimized end-to-end solution. We can enhance your product by adding value through all development and manufacturing processes. We can enhance your outcome by adding value through all development and manufacturing processes. We are Extrusion. We are Polymer Based Dosage Forms. We are Formulation of Highly Active dosage forms. We are Long Acting Implants. We are Solid Dosage Forms. We are Injection Molding. We are Aseptic Fill and Finish. We are Sever Pharma Solutions.

SE Tylose is the distribution organization of Shin-Etsu Chemical Co., Ltd. Japan and SE Tylose, Wiesbaden Germany and is registered in Wiesbaden. It is located at the Industrial Park Kalle-Albert in Wiesbaden. Together with our distributors, we are the exclusive business partners for our customers and multi national key accounts in the pharmaceutical- and the food industry. SE Tylose manages a regional, centralized warehouse for all products to be able to supply the customers in Europe on short-term base whenever necessary. SE Tylose will manage logistic for customers in other regions independent from Shin-Etsu´s production sites. For our pharma customers we offer with our technical application lab the possibility to optimize their processes if required. Our products are covering a very wide range of applications and they fully comply with FDA, USP/NF, JP and EP requirements. Pharmaceutical Excipients: Cellulose ether excipient is a pharmacologically inactive substance used as a carrier for the active ingredients in medication. PHARMACOAT® – Water-Soluble Film Coating Agent METOLOSE® – Binder and Thickening Agent METOLOSE® SR – Sustained release agent for hydrophilic matrix system L-HPC – Disintegrant with Binding Properties, Multifunctional Excipient HPMCP – Enteric Coating Agent Shin-Etsu AQOAT® – Enteric Coating Agent, Solid Dispersion Polymer Tylopur® – Low- and high viscosity Hypromellose

Siegfried is a globally leading outsourcing partner, providing tailor-made services that seamlessly integrate into the value chain of our customers. We offer contract development and manufacturing of APIs and finished dosage forms. Through our integrated approach we ensure a comprehensive range of services from process development and optimization to registration, production, packaging and logistics.
As a fully integrated CDMO, Siegfried is one of the few organizations today that can carry out the development and manufacturing of APIs and finished dosage forms under one roof. This unique combination of know-how and experience makes us the most trusted partner in the pharmaceutical industry.
Founded in 1873 in Zofingen, Switzerland, today we operate a global network of 12 sites on three continents. Our workforce of more than 3,700 highly skilled professionals is committed to take the innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide.

As the premier, independently owned CDMO with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions (Simtra) offers world-class cGMP sterile fill and finish, technical expertise, quality service, and a uniquely collaborative approach to support customers’ strategic objectives.

Biotech and pharmaceutical companies partner with Simtra when they need to take their molecule to market, whether launching an innovation globally, improving a formulation, or proactively mitigating risk to grow their business.

Simtra is also strengthening its development and pre-commercial services (DPCS) to support clients in accelerating their molecules from development to commercialization. This initiative builds upon Simtra’s extensive foundation in formulation, lyophilization development, and fill-finish capabilities, particularly for highly potent molecules.

Skyepharma is a France-based expert CDMO specializing in the formulation, development, and production of complex oral dosage forms, particularly those requiring customized modified-release profiles.

We offer a comprehensive range of services, from early-stage development to industrial-scale manufacturing and packaging, tailored to meet the specific needs of our partners.

Our team of scientific experts, supported by proprietary patented technologies, has a proven track record in formulation development, reformulation, and technology transfer projects.

Operating from our GMP-certified facility in Saint-Quentin-Fallavier, near Lyon, Skyepharma is approved by major health authorities including the FDA, ANVISA, and Korean MFDS. We proudly serve a global client base with a consistently high level of quality, service, and regulatory compliance.

Syngene International Limited is a leading Contract Research & Development/Manufacturing Organization (CRO/CDMO) with 450+ active clients and 400+ patent credits. We have 30+ years of rich experience working with global clients across the Drug Discovery and Development continuum.

What sets us apart, is our full-service, integrated capabilities all under one roof that lower the cost of innovation and enable faster approval and commercialization of your drug development product.

Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, we help you – our customers in the global pharmaceutical and food industries – to improve people's lives. For that we look back on more than 160 years of experience. In the pharma sector, our intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of your liquid and solid pharmaceuticals. In the food industry, our flexible and reliable technologies produce and package confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for your smooth production processes. In everything we do, our more than 30 sites in almost 20 countries keep a firm eye on our impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions.

UniD is a CDMO fully dedicated to polymer long-acting formulations for the sustained release and local delivery of drugs, to improve patient adherence and quality of life. Our integrated platform is accessible to life science partners and biotech wishing to leverage our formulation technology and over 20 years of expertise to develop unique polymer-based dosage forms, with the support of our experts, from proof of concept to commercialization.

WuXi STA, an integrated part of WuXi AppTec, is an industry-leading pharmaceutical development and manufacturing capability and technology platform serving the life sciences industry with operations across North America, Europe and Asia. As an innovative Contract Development, and Manufacturing Organization (CDMO) for small molecule new drug development, WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions from preclinical to commercial uses.

At XEDEV, we support your product development journey by combining extensive formulation and process expertise with state-of-the art manufacturing capacity.

We specialize in formulation and process development for solid drug products. Leveraging our extensive expertise, we design customized solutions to meet the requirements of each customer, ensuring advanced and efficient outcomes. Furthermore, XEDEV provides manufacturing services for R&D and GMP batches, supporting PK, Tox, Phase I and II clinical studies. Our flexible production capabilities range from small-scale to large-scale batch productions, accommodating your specific needs.

At XEDEV, we pride ourselves on being more than a service provider – we’re an extension of your team. With strong communication and collaboration at the core of our approach, we ensure a seamless and productive partnership. Contact XEDEV today to learn more about how we can support your development and manufacturing needs.

Find out more at www.xedev.com.

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.